OTC · MRZM
Healthcare · Biotechnology
$0.00
Up+$0.00 (+0.00%)
Updated Sep 20, 2026, 10:34 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
MRZM does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning MRZM.
MRZM research
Company profile and research snapshot.
MARIZYME INC
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
GlobeNewswire Inc. · Apr 16, 2024
JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN) to advance the commercialization of Marizyme’s first-in-class FDA cleared product, DuraGraft™.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MRZM.
No results
No recent SID articles mention MRZM.
